180 Life Sciences’ (ATNF) Sell (E+) Rating Reaffirmed at Weiss Ratings

Weiss Ratings reiterated their sell (e+) rating on shares of 180 Life Sciences (NASDAQ:ATNF) in a report published on Saturday,Weiss Ratings reports.

180 Life Sciences Stock Up 7.6 %

Shares of 180 Life Sciences stock opened at $1.13 on Friday. 180 Life Sciences has a twelve month low of $0.98 and a twelve month high of $17.75. The firm’s 50-day moving average price is $1.32 and its 200 day moving average price is $2.01.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in 180 Life Sciences stock. Rathbones Group PLC bought a new position in 180 Life Sciences Corp. (NASDAQ:ATNF) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm bought 69,995 shares of the company’s stock, valued at approximately $127,000. Rathbones Group PLC owned approximately 2.20% of 180 Life Sciences at the end of the most recent reporting period. 4.07% of the stock is owned by institutional investors.

About 180 Life Sciences

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor.